How big is the Europe Insulin Drugs Market?

The Europe Insulin Drugs Market size is expected to reach USD 5.95 billion in 2024 and grow at a CAGR of 4.89% to reach USD 7.55 billion by 2029. Read More

What is the current Europe Insulin Drugs Market size?

In 2024, the Europe Insulin Drugs Market size is expected to reach USD 5.95 billion. Read More

Who are the key players in Europe Insulin Drugs Market?

Novo Nordisk, Sanofi, Eli Lilly, AstraZeneca and Biocon are the major companies operating in the Europe Insulin Drugs Market. Read More

What years does this Europe Insulin Drugs Market cover, and what was the market size in 2023?

In 2023, the Europe Insulin Drugs Market size was estimated at USD 5.66 billion. The report covers the Europe Insulin Drugs Market historical market size for years: 2018, 2019, 2020, 2021, 2022 and 2023. The report also forecasts the Europe Insulin Drugs Market size for years: 2024, 2025, 2026, 2027, 2028 and 2029. Read More

Europe Insulin Market - Manufacturers, Share & Price

Europe Insulin Market Size & Share Analysis - Growth Trends & Forecasts (2024 - 2029)

The European Insulin Drugs Market is Segmented Into Type (basal or Long-Acting Insulins, Bolus or Fast-Acting Insulins, Traditional Human Insulins, Combination Insulins, And Biosimilar Insulins) and Geography (the United Kingdom, Germany, France, Russia, Spain, Italy, And the Rest of Europe). The Report Offers the Value (in USD) and Volume (in Units) for the Above Segments.

Europe Insulin Drugs Industry Overview

The European insulin drug market is highly consolidated in nature due to the presence of only a few major companies operating globally as well as regionally. Mergers and acquisitions between players in the recent past have helped companies strengthen their market presence. Eli Lilly and Boehringer Ingelheim have an alliance to develop and commercialize Abasaglar (Insulin Glargine).